Platform
Features
Pricing
0 followers
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
Industries
Headquarters
Employees
Links
Dan Kemp
This company has no teams yet
Calico
6 followers
Qualigen Therapeutics
3 followers
Caribou Biosciences
2 followers
89bio
Pyxis Oncology
PepGen
BioAge
Entos
1 follower
Cargo
Capricor Therapeutics
Paradromics
Explore companies